Invention Grant
- Patent Title: Tricyclic compounds and compositions as kinase inhibitors
-
Application No.: US16062680Application Date: 2016-12-15
-
Publication No.: US10377770B2Publication Date: 2019-08-13
- Inventor: Robert John Aversa , Matthew T. Burger , Michael Patrick Dillon , Thomas A. Dineen, Jr. , Rajesh Karki , Savithri Ramurthy , Vivek Rauniyar , Richard Robinson , Patrick James Sarver
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Scott W. Reid
- International Application: PCT/IB2016/057633 WO 20161215
- International Announcement: WO2017/103824 WO 20170622
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D491/04 ; C07D498/04 ; A61P35/00 ; C07D491/044

Abstract:
The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.
Public/Granted literature
- US20180362542A1 TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS Public/Granted day:2018-12-20
Information query